Fortrea Holdings $FTRE spun off from LabCorp with bold promises of growth and profitability—but insiders now face a lawsuit over alleged securities fraud. In this episode of Bulls & Betrayal, we dive into missed earnings, crumbling contract pipelines, and insider stock sales—all while the company talked up tech upgrades and margin magic. Perfect for investors, biotech watchers, and Wall Street accountability junkies.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Hit ZLK.com for more on the case and follow us for the next corporate faceplant.

Civitas Resources $CIVI promised strong production and growth—but behind the scenes, well counts dropped, debt ballooned, and executives vanished. In this episode of Bulls & Betrayal, we expose how upbeat forecasts masked real operational decline and why investors are now suing over sudden stock losses and surprise layoffs. If you’re into energy markets, corporate accountability, or just love a good Wall Street takedown, this one’s for you.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Check out ZLK.com to learn more or join the class action.

Biotech hopeful Iovance $IOVA promised a blockbuster launch of its cancer drug Amtagvi—forecasting nearly half a billion in revenue. But when reality hit, it came crashing down. In this episode of Bulls & Betrayal, we uncover how lofty projections, slow treatment rollout, and alleged internal knowledge of infrastructure issues led to a brutal 45% stock plunge. Ideal for investors, healthcare analysts, and corporate truth-seekers. Expect biotech drama, class action insights, and sharp market analysis.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Learn more or join the case at ZLK.com